REGENXBIO Statistics
NASDAQ: RGNXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
7.16-0.02 (-0.28%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
REGENXBIO by the numbers
REGENXBIO has a market capitalization of $473.4 million based on 66.12M shares outstanding. With trailing EPS of $-3.20, REGENXBIO is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 4.6% below its 50-day average and 18.5% below its 200-day average.
Average daily trading volume is 1.39M shares, or about $9.9 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
RGNX valuation vs. peer median
| Metric | RGNX | Peer median | Difference |
|---|---|---|---|
| Market cap | $473.44M | $469.28M | +1% |
| Avg. volume | 1.39M | 390.07K | +256% |
Peer median across 8 companies: SANA, DNA, FENC, VALN, ETRA, IRLA, PROK, TECX.
Valuation
- Market cap
- $473.44M
- Price / sales (latest FY)
- 2.78
- EPS (TTM)
- $-3.20
- Shares outstanding
- 66.12M
Price and trading
- Previous close
- 7.18
- Open
- 7.00
- Day range
- 6.86 – 7.30
- 52-week range
- 5.46 – 16.19
- 52-week change
- -39.32%
- Beta
- —
- Volume
- 1.05M
- Average volume
- 1.39M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 5, 2026
Additional statistics
- Market Cap
- 473.44M
- Forward Pe
- -2.33
- Eps
- -3.20
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 16.19
- Week52 Low
- 5.46
- Avg Volume
- 1.39M
- Shares Outstanding
- 66.12M
- Ma50
- 7.51
- Ma200
- 8.79
- Earnings Date
- Nov 5, 2026
- Pct From52w High
- -55.78%
- Pct From52w Low
- 31.26%